HIV type 1 subtype diversity and drug resistance among HIV Type 1-infected kenyan patients initiating antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 25, Issue 12, 2009, Pages 1211-1217

  Lihana, Raphael W ^a,b   Khamadi, Samoel A ^a   Lubano, Kizito ^a   Lwembe, Raphael ^a   Kiptoo, Michael K ^a   Lagat, Nancy ^a   Kinyua, Joyceline G ^a   Okoth, Fredrick A ^a   Songok, Elijah M ^a,c   Makokha, Ernest P ^a   Ichimura, Hiroshi ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, ENV; GENES, POL; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 73149114901     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0007     Document Type: Article

References (49)

1. Preston BD, Poiesz BJ, and Loeb LA: Fidelity of HIV-1 reverse transcriptase. Science 1988;242(4882):1168-1171.
2. DrosopoulosWCand Prasad VR: Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro. J Virol 1998;72(5):4224-4230.
3. Brander C and Walker BD: Gradual adaptation of HIV to human host populations: Good or bad news? Nat Med 2003;9(11):1359-1362.
4. Rowland-Jones SL: Timeline: AIDS pathogenesis: What have two decades of HIV research taught us? Nat Rev Immunol 2003;3(4):343-348.
5. Spira S, Wainberg MA, Loemba H, et al.: Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003;51(2): 229-240.
6. Apetrei C, Marx PA, and Smith SM: The evolution of HIV and its consequences. Infect Dis Clin North Am 2004; 18(2):369-394.
7. McCutchan FE: Understanding the genetic diversity of HIV- 1. AIDS 2000;14(Suppl 3):S31-44.
8. Peeters M and Sharp PM: Genetic diversity of HIV-1: The moving target. AIDS 2000;14(Suppl)3:S129-S140.
9. Peeters M, Esu-Williams E, Vergne L, et al.: Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses 2000;16(4):315-325.
10. Masquelier B, Bhaskaran K, Pillay D, et al.: Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005;40(5):505-511.
11. Vercauteren J, Derdelinckx I, Sasse A, et al.: Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24(3):355-362.
12. Escoto-Delgadillo M, Vázquez-Valls E, Ramírez- Rodríguez M, et al.: Drug resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005;6:403-409.
13. Joint United Nations Programme on HIV/AIDS/World Health Organization. Treating 3 Million by 2005: Making It Happen-The WHO Strategy. Geneva, Switzerland: World Health Organization, 2005. Available at www.who.int/ 3by5/en. Accessed December 17, 2008.
14. del Rio C: Updated antiretroviral treatment guidelines from DHHS and EACS. AIDS Clin Care 2008;20(1):7.
15. AIDS Patient Care and STDs: Antiviral Briefs 2008;22(1): 85-88. doi:10.1089/apc.2007.9962.
16. Konings FA, Zhong P, Agwara M, et al.: Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses 2004;20(1):105-109.
17. Ndembi N, Abraha A, Pilch H, et al.: Molecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: Evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B. J Clin Microbiol 2008; 46(1):177-184.
18. Koizumi Y, Ndembi N, Miyashita M, et al.: Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr 2006; 43(1):15-22.
19. Bartolo, I, Casanovas, J, Bastos R, et al.: HIV-1 Genetic diversity and transmitted drug resistance in health care set-
20. Bussmann H, Novitsky V, Wester W, et al.: HIV-1 subtype C drug resistance background among ARV-naive adults in Botswana. Antivir Chem Chemother 2005;16(2):103-115.
21. Vardavas R and Blower S: The emergence of HIV transmitted resistance in Botswana: "When will the WHO detection threshold be exceeded?" PLoS ONE 2007; 2(1):e152.
22. Ndembi N, Lyagoba F, Nanteza B, et al.: Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses 2008; 24(6):889-895.
23. Somi GR, Kibuka T, Diallo K, et al.: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir Ther 2008;13(Suppl 2):77-82.
24. Kamoto K, Aberle-Grasse J, et al.: Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008;13(Suppl 2):83-87.
25. World Health Organization, Joint United Nations Programme on HIV/AIDS (UNAIDS). Progress on global access to HIV antiretroviral therapy: A report on "3 by 5" and beyond, 2006. Geneva, Switzerland: World Health Organization, Joint United Nations Programme on HIV/AIDS (UNAIDS), 2006. Available at http://www.who.int/hiv/ fullreport-en-highres.pdf.
26. Kenya Ministry of Health. National AIDS and STD Control Programme (NASCOP). Available at www.aidskenya. org/publications. Accessed April 28, 2009.
27. World Health Organization. Antiretroviral therapy. Geneva, Switzerland: World Health Organization, 2008. Available at www.who.int/hiv/topics/treatment/ en. Accessed December 17, 2008.
28. World Health Organization. Priority interventions: HIV/ AIDS prevention, treatment and care in the health sector, 2008. Available atwww.who.int/hiv/pub/ priorityinterventions/ en. Accessed December 17, 2008.
29. Bennett DE, Myatt M, Bertagnolio S, et al.: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13(Suppl 2):25-36.
30. Chung MH, Kiarie JN, Richardson BA, et al.: Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2007;46(4):472-478.
31. Chung MH, Kiarie JN, Richardson BA, et al.: Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: A phase II randomized clinical trial. Antivir Ther 2008;13(6):799-807.
32. Lehman DA, Chung MH, John-Stewart GC, et al.: HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 2008;22(12): 1475-1485.
33. van't Hoog AH, Mbori-Ngacha DA, Marum LH, et al.: Preventing mother-to-child transmission of HIV in Western Kenya: Operational issues. J Acquir Immune Defic Syndr 2005;40(3):344-349.
34. Lwembe R, Ochieng W, Panikulam A, et al.: Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007;79(7):865-872.
35. Songok EM, Lwembe RM, Kibaya R, et al.: Active generation and selection for HIV intersubtype A/D recombinant forms in a coinfected patient in Kenya. AIDS Res Hum Retroviruses 2004;20:255-258.
36. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16(5):138-145.
37. Wainberg MA: Perspectives on antiviral drug development. Antiviral Res 2009;81(1):1-5.
38. Paredes R, Sagar M, Marconi VC, et al.: In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 2009;83(4):2038-2043.
39. Turriziani O, Russo G, Lichtner M, et al.: Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008;24(6):781-785.
40. de Mendoza C, Rodriguez C, García F, et al.: Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother 2007;59(4):698-704.
41. Bi X, Gatanaga H, Ida S, et al.: Emergence of protease inhibitor resistance-associatedmutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003;34(1):1-6.
42. Kowalski J, Gange SJ, Schneider MF, et al.: Relationship of injection drug use, antiretroviral therapy resistance, and genetic diversity in the HIV-1 pol gene. J Acquir Immune Defic Syndr 2009;50(4):381-389.
43. Lihana RW, Khamadi SA, Lwembe RM, et al.: The changing trend of HIV type 1 subtypes in Nairobi. AIDS Res Hum Retroviruses 2009;25(3):337-342.
44. Land AM, Luo M, Pilon R, et al.: High prevalence of genetically similar HIV-1 recombinants among infected sex workers in Nairobi, Kenya. AIDS Res Hum Retroviruses 2008;24(11):1455-1460.
45. van de Vijver DA, Wensing AM, Angarano G, et al.: The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006;41(3):352-360.
46. Hamers RL, Derdelinckx I, van Vugt M, et al.: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008;13(5):625-639.
47. Geretti AM, Harrison L, Green H, et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48(9):1296-1305.
48. Doualla-Bell, Avalos A, Brenner B, et al.: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with Didanosine-based regimens. Antimicrobial Agents Chemother 2006;50:4182-4185.
49. Armstrong KL, Lee TH, and Essex M: Replicative capacity differences of thymidine analog resistance mutations in subtype B and C human immunodeficiency virus type 1. J Virol 2009;83(9):4051-4059